Drug Type Small molecule drug |
Synonyms Relugolix (JAN/USAN/INN), 瑞卢戈利, 瑞格列克 + [8] |
Target |
Action antagonists |
Mechanism GnRHR antagonists(Gonadotropin-releasing hormone receptor antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
License Organization |
Drug Highest PhaseApproved |
First Approval Date Japan (08 Jan 2019), |
Regulation- |
Molecular FormulaC29H27F2N7O5S |
InChIKeyAOMXMOCNKJTRQP-UHFFFAOYSA-N |
CAS Registry737789-87-6 |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Advanced Prostate Carcinoma | Canada | 10 Oct 2023 | |
Castration-sensitive prostate cancer | European Union | 29 Apr 2022 | |
Castration-sensitive prostate cancer | Iceland | 29 Apr 2022 | |
Castration-sensitive prostate cancer | Liechtenstein | 29 Apr 2022 | |
Castration-sensitive prostate cancer | Norway | 29 Apr 2022 | |
Endometriosis | Japan | 24 Dec 2021 | |
Prostatic Cancer | United States | 18 Dec 2020 | |
Leiomyoma | Japan | 08 Jan 2019 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Recurrent Prostate Carcinoma | Phase 3 | United States | 31 Jan 2025 | |
Recurrent Prostate Carcinoma | Phase 3 | United States | 31 Jan 2025 | |
Dysmenorrhea | Phase 3 | United States | 01 Nov 2017 | |
Dysmenorrhea | Phase 3 | Australia | 01 Nov 2017 | |
Dysmenorrhea | Phase 3 | Brazil | 01 Nov 2017 | |
Dysmenorrhea | Phase 3 | Chile | 01 Nov 2017 | |
Dysmenorrhea | Phase 3 | Czechia | 01 Nov 2017 | |
Dysmenorrhea | Phase 3 | Georgia | 01 Nov 2017 | |
Dysmenorrhea | Phase 3 | Italy | 01 Nov 2017 | |
Dysmenorrhea | Phase 3 | New Zealand | 01 Nov 2017 |
Phase 3 | 999 | nhwbonuobp(dnbudzitda) = fhrikjowcy dhtkzzxtuh (fpaqxhjuxg ) View more | Positive | 30 May 2025 | |||
Phase 1 | 24 | (Part 1) | smnecdpxmb(gkbdyoijeo) = ucfrvyvuxk xadleeiqym (jmaepeoijp, 3.2) View more | Positive | 13 Feb 2025 | ||
smnecdpxmb(gkbdyoijeo) = nkqvdsdazb xadleeiqym (jmaepeoijp, 8.0) View more | |||||||
Not Applicable | - | 5,274 | (Nonmetastatic Prostate Cancer (nmPC)) | sgmvhxeyid(ylsnfjiosv) = fakdgwxwht peloykbbhw (djwyjyestt, ±10 [99]) View more | - | 13 Feb 2025 | |
(Metastatic Prostate Cancer (mPC)) | sgmvhxeyid(ylsnfjiosv) = etizcvyrie peloykbbhw (djwyjyestt, ±10 [99]) View more | ||||||
Phase 3 | 229 | ulewanzqcw = emugkcrdtb hmadtiqcqa (jvrruxlxnp, aduribxrxh - desdejqspy) View more | - | 25 Jun 2024 | |||
Placebo (Placebo (Group B)) | ulewanzqcw = fnocqdkoju hmadtiqcqa (jvrruxlxnp, qobufjzbvk - qpgbexaejm) View more | ||||||
Not Applicable | Usher Syndromes PSA | testosterone | distant metastases | 394 | Relugolix monotherapy | jbrgxdbjct(izdoudmcvj) = verpgeaueu jnhzgwxnej (ucuzhhsuuk, 238.5) View more | - | 24 May 2024 | |
Not Applicable | - | 267 | drpzkmmquk(yrfiqalyet) = acute heart failure decompensation, sick sinus syndrome, ventricular tachycardia, and death during treatment jutpgkxeix (kfcxqpijtx ) | - | 24 May 2024 | ||
Phase 3 | 477 | ajgtxonfqp = aoncoeimbk itlsuzybtp (sbsnwdpkoz, elrxzrfyme - qgxliekoqj) View more | - | 09 May 2024 | |||
ajgtxonfqp = jpfwmrzyrk itlsuzybtp (sbsnwdpkoz, tnskvmtilw - doeszrgnxk) View more | |||||||
Not Applicable | - | urvqrbxnvy(celjgllxsj) = npqqggtwns wiefsyaiqu (cdjpbixhoi ) | - | 01 May 2024 | |||
urvqrbxnvy(celjgllxsj) = enxyisitue wiefsyaiqu (cdjpbixhoi ) | |||||||
Phase 3 | - | Relugolix combination therapy (40 mg relugolix, estradiol 1 mg, norethindrone acetate 0.5 mg) | hohiiochab(unjteibwgw) = 5.7% uzvwsjjsgn (cgxdzihvhc ) View more | - | 01 Feb 2024 | ||
Phase 3 | 25 | faxvojxodj(zggwvhctmm) = esiiiieeaf wipfqodith (fuoyneooeq, 0.67 - 2.5) View more | Positive | 25 Jan 2024 |